Gut dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis

Table 2 Baseline characteristics of the patients with TAK

	TAK (n = 76)
Duration of disease, years (IQR)^a	12 (5–30)
Newly diagnosed, n, %	19, 25.0
Treatment naïve, n, %	17, 22.4
Inflammatory bowel disease, n, %	8, 10.5
Numano scale
I, n, %	4, 5.3
IIa, n, %	13, 17.1
IIb, n, %	32, 42.1
III, n, %	0, 0
IV, n, %	1, 1.3
V, n, %	26, 34.2
HLA-B52 positivity, n, %	46, 60.5
CRP, mg/dL, mean ± SD	0.34 ± 1.1
ESR, mm/hour, mean ± SD^b	14.2 ± 18.8
Modified NIH score ≥ 2^c, n, %	14, 18.4
Triglyceride, mg/dL, mean ± SD^d	111 ± 63
LDL cholesterol, mg/dL, mean ± SD^d	106 ± 29
HDL cholesterol, mg/dL, mean ± SD^d	66 ± 17
Smoking (current or past), n, %	18, 23.7
Aortic aneurysm, n, %	7, 9.2
Previous cardiovascular surgery, n, %	15, 19.7
Previous endovascular treatment, n, %	9, 11.8
Medication
Antiplatelet, n, %	44, 57.9
Glucocorticoid, n, %	52, 68.4
Mean dose of prednisolone (mg/day), mean ± SD	5.2 ± 4.9
Methotrexate, n, %	8, 10.5
Azathioprine, n, %	8, 10.5
Cyclosporine, n, %	1, 1.3
5-aminosalicyclic acid, n, %	6, 7.9
Tocilizumab, n, %	30, 39.5
TNF inhibitor, n, %	3, 3.9

CRP C reactive protein, ESR erythrocyte sedimentation rate, HDL high-density lipoprotein, HLA human leukocyte antigen, IQR interquartile range, LDL low-density lipoprotein, NIH National Institute of Health, TAK Takayasu arteritis, TNF tumour necrosis factor
^aThe duration of disease was unknown in 19 patients
^bData were missing in nine patients
^cConsidered as patients with active TAK
^dData were missing in five patients. A few data of triglyceride were not under fasting condition

ISSN: 1478-6362